Why Pradaxa?
An image denoting the 'why Pradaxa (Dabigatran)' section on the site

Pradaxa efficacy in deep vein thrombosis and pulmonary embolism (DVT/PE)

Experienced stroke prevention also approved for your DVT1,2

Pradaxa provides comparable efficacy to warfarin in DVT with superior bleeding reductions you can rely on.1–4

 

An image showing the number of patients across the four Pradaxa (Dabigatran) clinical trials

ONLY Pradaxa has been compared head-to-head with warfarin in a long-term study for up to 36 months.4

 

 

An image showing length of time for Pradaxa (Dabigatran) vs. other novel oral anticoagulants (NOACs)

Pradaxa efficacy in primary prevention of venous thromboembolism

Pradaxa provides efficacy comparable to enoxaparin.5,6

After either total hip or total knee replacement, Pradaxa patients showed similar incidence of total VTE and all-cause mortality to enoxaparin.5,6
Pradaxa significantly lowered incidence of major VTE and VTE-related mortality after hip replacement, compared with enoxaparin.5

  • Pradaxa 220 mg, 2.2% vs enoxaparin 40 mg, 4.2% (p=0.029)

Pradaxa and enoxaparin had similar incidence of major VTE and VTE-related mortality after knee replacement.6

  • Pradaxa 220 mg, 2.6% vs enoxaparin 40 mg, 3.5% (p=0.38)

Pradaxa safety in DVT/PE

How does the bleeding risk of Pradaxa compare with warfarin in DVT/PE?

Compared with warfarin, Pradaxa 150 mg BID significantly reduced the risk of major or clinically relevant non-major (CRNM) bleeding, major bleeding and any bleeding.1,3,4

 

Pradaxa vs. Warfarin: risk reduction in deep vein thrombosis (DVT) & pulmonary emboli (PE)

Pradaxa safety in primary prevention of venous thromboembolism

How does the bleeding risk of Pradaxa compare with enoxaparin in VTE?

After total hip or knee replacement, Pradaxa has a safety profile comparable to enoxaparin for both major and minor bleeding.5,6

  • Pradaxa 220 mg and enoxaparin had a similar incidence of major and minor bleeding events after total hip and total knee replacement5,6

Pradaxa safety in pVTEp

An image showing the percentage of patients with major bleeding for Pradaxa vs. Enoxaparin

 

Minor bleeding events were also comparable between Pradaxa and enoxaparin:5,6

  • Hip replacement: Pradaxa 220 mg, 6.0% vs enoxaparin 40 mg, 5.4%
  • Knee replacement: Pradaxa 220 mg, 8.8% vs enoxaparin 40 mg, 9.9%
References: 
  1. Pradaxa Summary of Product Characteristics 2016. Boehringer Ingelheim.
  2. Boehringer Ingelheim. Data on file.
  3. Schulman S et al. N Engl J Med 2009;361(24):2342–2352.
  4. Schulman S et al. N Engl J Med 2013;368(8):709–718.
  5. Eriksson Bl et al. J Thromb Haemost 2011;105:721–729.
  6. Eriksson Bl et al. J Thromb Haemost 2007;5:2178–2185.